PHVS Pharvaris
- 23.410
- +0.060+0.26%
Pharvaris News
Form 144 | Pharvaris(PHVS.US) Officer Proposes to Sell 417.4K in Common Stocks
SEC FILLINGS DISCLOSED/ Apr 23, $Pharvaris(PHVS.US)$ Officer MORGAN CONN intends to sell 20,000 shares of its common stock on Apr 23, with a total market value of approximately $417.4K. MORGAN CONN
Express News | Morgan Stanley Maintains Overweight on Pharvaris, Maintains $34 Price Target
Form 144 | Pharvaris(PHVS.US) Officer Proposes to Sell 311.9K in Common Stocks
SEC FILLINGS DISCLOSED/ Apr 15, $Pharvaris(PHVS.US)$ Officer MORGAN CONN intends to sell 14,242 shares of its common stock on Apr 15, with a total market value of approximately $311.9K. Source: Ann
Pharvaris Is Maintained at Overweight by Morgan Stanley
Pharvaris Is Maintained at Overweight by Morgan Stanley
Express News | Morgan Stanley Maintains Overweight on Pharvaris, Lowers Price Target to $34
Express News | Pharvaris Shares Are Trading Lower After the Company Filed for a Mixed Shelf Offering
Pharvaris Earns Buy Rating as Deucrictibant Shows Promising Progress in HAE Treatment
Pharvaris Files for Automatic Mixed Securities Shelf
Express News | Pharvaris NV Files for Mixed Shelf Offering; Size Not Disclosed- SEC Filing
Pharvaris N.V.'s High-Stakes Gamble: Navigating Clinical Trials and Regulatory Hurdles for Market Success
Buy Rating Affirmed for Pharvaris on Strong HAE Drug Potential and Solid Financials
Pharvaris Price Target Raised to $50.00/Share From $49.00 by JMP Securities
Pharvaris Price Target Raised to $50.00/Share From $49.00 by JMP Securities
Wedbush Reaffirms Their Buy Rating on Pharvaris (PHVS)
Pharvaris Excels in HAE Treatment Advances
Buy Rating Affirmed for Pharvaris on Strong Clinical Progress and Financial Stability
Pharvaris Narrows Q4 Net Loss; Hires New CFO
Pharvaris (PHVS) late Wednesday reported a Q4 net loss of 0.74 euros ($0.80) per diluted share, compared with a 1.16 euro loss a year earlier. Analysts polled by Capital IQ expected a 0.57 loss. As ex
Express News | Pharvaris Q4 EPS $(0.80) Misses $(0.58) Estimate
Pharvaris N.V. EPS €(0.74) Vs €(1.16) YoY; Cash And Cash Equivalents Were ~€391 Million As Of December 31, 2023
Fourth Quarter and Full Year 2023 Financial ResultsLiquidity Position. Cash and cash equivalents were approximately €391 million as of December 31, 2023, compared to approximately €162 million for Dec
Pharvaris 4Q Loss/Shr EUR0.74 >PHVS
Pharvaris 4Q Loss/Shr EUR0.74 >PHVS
Express News | Pharvaris Appoints David Nassif As Chief Financial Officer
Analysis
Price Target
No Data
